Product Description
ION269 is an investigational antisense oligonucleotide (ASO) medicine designed to lower the amount of amyloid precursor protein (APP) for the potential treatment of Alzheimer's disease (AD), which is initially being studied in adults with Down syndrome (DS) who have a genetic risk of developing AD. (Sourced from: https://www.ionis.com/science-and-innovation/pipeline)
Mechanisms of Action: APP Reducer
Novel Mechanism: Yes
Modality: Nucleic Acid
Route of Administration: Injection
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Ionis
Company Location: Western America
Company Founding Year: 1989
Additional Commercial Interests: None
Clinical Description
Countries in Clinic:
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 1: Alzheimer Disease|Down Syndrome
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT06673069 |
Hero | P1 |
Terminated |
Alzheimer Disease|Down Syndrome |
2025-12-03 |
12% |
2026-02-21 |
Recent News Events
Date |
Type |
Title |
|---|